Hims and Hers retreats from weight loss pill launch after regulatory crackdown
The telehealth firm abandoned its oral semaglutide pill after FDA warnings and a lawsuit from Novo Nordisk. Shares fell as growth prospects remain uncertain.
Insights:
Hims & Hers Health, Inc. announced plans to offer a compounded oral semaglutide pill for $49, only to withdraw the offering two days later following a warning from Marty Makary, the Commissioner of the U.S. Food and Drug Administration. This rapid sequence of events in the US 
US was immediately followed by a patent infringement lawsuit filed by Novo Nordisk A/S , which is based in DK 
DK. The incident has prompted swift regulatory and legal responses, highlighting the volatility of the current pharmaceutical landscape.
US was immediately followed by a patent infringement lawsuit filed by Novo Nordisk A/S , which is based in DK DK. The incident has prompted swift regulatory and legal responses, highlighting the volatility of the current pharmaceutical landscape.
